The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations
Article first published online: 3 DEC 2010
© 2010 The Authors; Brain Pathology © 2010 International Society of Neuropathology
Volume 21, Issue 1, pages 74–87, January 2011
How to Cite
Von Deimling, A., Korshunov, A. and Hartmann, C. (2011), The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations. Brain Pathology, 21: 74–87. doi: 10.1111/j.1750-3639.2010.00454.x
- Issue published online: 3 DEC 2010
- Article first published online: 3 DEC 2010
- Received 11 October 2010; accepted 11 October 2010.
For some, glioma biomarkers have been expected to solve common diagnostic problems in routine neuropathology service caused by insufficient material, technical shortcomings or lack of experience. Further, biomarkers should predict patient outcome and direct optimal therapy for the individual patient. Unfortunately, current biomarkers still fall somewhat short of these grand expectations. While there has been some progress, it has generally been slow and in small steps. In this review, the newest set of glioma biomarkers: O6-methylguanine-DNA methyltransferase (MGMT) methylation, BRAF fusion and IDH1 mutation are discussed. MGMT methylation is well established as a prognostic/predictive marker for glioblastoma; however, technical questions regarding testing remain, it is not currently utilized widely in guiding patient management, and it has proven to be of no assistance in diagnostics. In contrast, BRAF fusion and IDH1 mutation analyses promise to be very helpful for classifying and grading gliomas, while their potential predictive value has yet to be established.